Free Trial

Axsome Therapeutics (AXSM) Financials

Axsome Therapeutics logo
$102.99 -0.99 (-0.95%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$103.00 +0.01 (+0.01%)
As of 05/28/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Axsome Therapeutics

Annual Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
-287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Consolidated Net Income / (Loss)
-287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Net Income / (Loss) Continuing Operations
-287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Total Pre-Tax Income
-287 -238 -187 -130 -103 -68 -31 -29 -28 -12
Total Operating Income
-281 -232 -180 -125 -99 -67 -33 -27 -28 -9.20
Total Gross Profit
352 245 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
386 271 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue
386 271 50 0.00 0.00 - - - - -
Total Cost of Revenue
33 26 5.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue
33 26 5.20 0.00 0.00 - - - - -
Total Operating Expenses
633 476 225 125 99 67 33 27 28 9.20
Selling, General & Admin Expense
411 323 159 67 29 14 9.35 7.21 6.34 2.42
Research & Development Expense
187 98 58 58 70 54 23 20 21 6.78
Amortization Expense
6.39 6.38 4.14 0.00 0.00 - - - - -
Other Operating Expenses / (Income)
28 49 3.30 0.00 0.00 - - - - -
Total Other Income / (Expense), net
-6.57 -6.45 -7.34 -5.70 -3.81 -1.24 1.66 -1.99 -0.13 -3.29
Interest & Investment Income
-6.57 -6.45 -7.34 -5.70 -2.57 -1.24 -1.13 -1.34 -0.13 -0.74
Income Tax Expense
0.09 0.96 0.00 0.00 -0.05 - -0.22 - - -
Other Gains / (Losses), net
0.00 0.00 0.00 0.00 - 0.14 - 0.21 0.47 0.00
Basic Earnings per Share
($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Weighted Average Basic Shares Outstanding
47.91M 45.43M 40.66M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M
Diluted Earnings per Share
($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Weighted Average Diluted Shares Outstanding
47.91M 45.43M 40.66M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M
Weighted Average Basic & Diluted Shares Outstanding
48.77M 47.37M 43.52M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M

Quarterly Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Consolidated Net Income / (Loss)
-59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Net Income / (Loss) Continuing Operations
-59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Total Pre-Tax Income
-59 -75 -65 -79 -68 -99 -63 -68 -8.64 -61 -45
Total Operating Income
-57 -73 -63 -78 -67 -98 -62 -65 -6.37 -60 -42
Total Gross Profit
112 108 96 79 69 64 51 42 87 22 15
Total Revenue
121 119 105 87 75 72 58 47 95 24 17
Operating Revenue
121 119 105 87 75 72 58 47 95 24 17
Total Cost of Revenue
9.79 11 8.44 8.06 6.30 7.38 6.53 4.60 7.56 2.29 1.92
Operating Cost of Revenue
9.79 11 8.44 8.06 6.30 7.38 6.53 4.60 7.56 2.29 1.92
Total Operating Expenses
169 181 159 157 136 162 113 107 93 82 57
Selling, General & Admin Expense
121 113 96 104 99 87 83 79 74 61 41
Research & Development Expense
45 55 45 50 37 31 29 21 18 15 15
Amortization Expense
1.57 1.61 1.61 1.59 1.59 1.61 1.61 1.59 1.57 1.61 1.61
Other Operating Expenses / (Income)
1.51 11 16 2.16 -1.41 43 -0.18 6.05 -0.16 4.20 -0.04
Total Other Income / (Expense), net
-2.43 -2.21 -1.98 -1.30 -1.08 -0.70 -0.76 -2.73 -2.26 -1.32 -2.41
Interest & Investment Income
-2.43 -2.21 -1.98 -1.30 -1.08 -0.70 -0.76 -2.73 -2.26 -1.32 -2.41
Income Tax Expense
0.00 0.09 0.00 0.00 0.00 -0.33 -0.68 -0.62 2.58 - 0.00
Basic Earnings per Share
($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Weighted Average Basic Shares Outstanding
48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Diluted Earnings per Share
($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Weighted Average Diluted Shares Outstanding
48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Weighted Average Basic & Diluted Shares Outstanding
49.24M 48.77M 48.46M 48.00M 47.50M 47.37M 47.32M 47.19M 43.57M 43.52M 43.43M

Annual Cash Flow Statements for Axsome Therapeutics

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
-71 185 114 -97 -36 206 -20 -2.60 -11 45
Net Cash From Operating Activities
-128 -145 -117 -108 -78 -46 -30 -26 -21 -7.44
Net Cash From Continuing Operating Activities
-128 -145 -117 -108 -78 -46 -30 -26 -21 -7.44
Net Income / (Loss) Continuing Operations
-287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Consolidated Net Income / (Loss)
-287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Depreciation Expense
0.53 0.46 0.26 0.08 0.02 0.04 0.05 0.04 0.02 0.00
Amortization Expense
10 8.95 5.62 1.08 0.84 0.65 0.38 0.47 0.07 0.05
Non-Cash Adjustments To Reconcile Net Income
114 113 41 21 23 6.12 -1.04 2.72 2.03 3.78
Changes in Operating Assets and Liabilities, net
34 -28 24 0.32 0.41 15 1.52 -0.81 3.80 0.94
Net Cash From Investing Activities
-0.27 -0.58 -54 -0.31 -0.05 -0.02 -0.03 -0.01 -0.10 -0.02
Net Cash From Continuing Investing Activities
-0.27 -0.58 -54 -0.31 -0.05 -0.02 -0.03 -0.01 -0.10 -0.02
Purchase of Property, Plant & Equipment
-0.27 -0.58 -0.70 -0.31 -0.05 -0.02 -0.03 -0.01 -0.10 -0.02
Acquisitions
0.00 0.00 -53 0.00 0.00 - - - - -
Net Cash From Financing Activities
58 331 285 11 42 252 10 24 9.97 53
Net Cash From Continuing Financing Activities
58 331 285 11 42 252 10 24 9.97 53
Repayment of Debt
0.00 -1.44 -0.49 -0.31 -23 -7.24 -3.36 -0.28 -0.06 0.00
Repurchase of Common Equity
-0.82 -16 -6.98 -0.22 - 0.00 - - - -
Issuance of Debt
0.00 85 45 0.00 50 20 0.00 0.00 10 7.44
Issuance of Common Equity
71 259 250 7.44 14 238 13 24 0.00 46
Other Financing Activities, net
-13 4.37 -2.97 4.23 1.05 1.39 0.51 0.48 0.03 0.00
Cash Interest Paid
20 17 7.69 4.63 2.10 1.29 0.77 0.87 0.05 -

Quarterly Cash Flow Statements for Axsome Therapeutics

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-14 -12 12 -16 -55 -30 -21 191 46 -27 154
Net Cash From Operating Activities
-43 -26 -19 -30 -53 -30 -54 -55 -5.82 -28 -23
Net Cash From Continuing Operating Activities
-43 -26 -19 -30 -53 -30 -54 -55 -5.82 -28 -23
Net Income / (Loss) Continuing Operations
-59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Consolidated Net Income / (Loss)
-59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Depreciation Expense
0.15 0.13 0.13 0.14 0.13 0.13 0.14 0.10 0.09 0.09 0.07
Amortization Expense
2.65 2.65 2.60 2.49 2.32 2.06 2.23 2.50 2.16 1.95 2.06
Non-Cash Adjustments To Reconcile Net Income
23 33 38 24 19 63 15 23 13 15 8.67
Changes in Operating Assets and Liabilities, net
-10 13 5.08 23 -6.81 3.43 -8.66 -14 -9.63 17 11
Net Cash From Investing Activities
-0.34 -0.03 -0.09 -0.05 -0.10 -0.01 -0.37 -0.13 -0.07 -0.18 -0.07
Net Cash From Continuing Investing Activities
-0.34 -0.03 -0.09 -0.05 -0.10 -0.01 -0.37 -0.13 -0.07 -0.18 -0.07
Purchase of Property, Plant & Equipment
-0.34 -0.03 -0.09 -0.05 -0.10 -0.01 -0.37 -0.13 -0.07 -0.18 -0.07
Net Cash From Financing Activities
29 14 30 14 -1.19 -0.00 33 246 52 1.07 177
Net Cash From Continuing Financing Activities
29 14 30 14 -1.19 -0.00 33 246 52 1.07 177
Repurchase of Common Equity
-0.39 -0.33 -0.26 - - - -2.05 - - - -5.22
Issuance of Common Equity
20 18 43 - - -11 45 - - 6.25 180
Other Financing Activities, net
10 -2.99 -12 3.34 -1.19 10 -8.75 4.93 -2.22 -5.19 1.97
Cash Interest Paid
4.59 4.76 5.02 5.01 4.90 4.87 4.73 3.92 3.22 2.57 2.53

Annual Balance Sheets for Axsome Therapeutics

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
568 588 331 88 186 221 15 36 38 49
Total Current Assets
485 504 246 87 184 220 15 35 38 49
Cash & Equivalents
315 386 201 86 184 220 14 34 37 48
Accounts Receivable
142 95 38 0.00 - - - - - -
Inventories, net
16 15 4.32 0.00 - - - - - -
Prepaid Expenses
12 8.12 2.78 0.05 0.15 0.41 1.25 1.28 1.38 1.00
Plant, Property, & Equipment, net
0.58 0.85 0.72 0.28 0.05 0.03 0.05 0.07 0.10 0.02
Total Noncurrent Assets
83 83 85 0.98 2.06 0.14 0.11 0.19 0.11 0.03
Goodwill
12 12 10 0.00 - - - - - -
Intangible Assets
47 53 60 0.00 - - - - - -
Other Noncurrent Operating Assets
24 18 15 0.98 2.06 0.14 0.11 0.19 0.11 0.03
Total Liabilities & Shareholders' Equity
568 588 331 88 186 221 15 36 38 49
Total Liabilities
511 397 222 72 72 42 14 19 17 2.63
Total Current Liabilities
230 139 97 23 23 24 11 12 7.17 2.63
Short-Term Debt
8.29 6.41 5.90 0.00 - 2.60 3.29 3.27 0.27 0.00
Accounts Payable
220 131 90 22 22 22 7.53 6.11 6.90 2.63
Other Current Liabilities
1.84 1.27 0.43 0.62 1.22 0.00 - 2.79 0.00 -
Total Noncurrent Liabilities
281 258 125 49 49 17 3.62 6.66 9.47 0.00
Long-Term Debt
181 178 94 49 48 17 3.62 6.66 9.47 0.00
Capital Lease Obligations
2.94 0.00 - - - - - - - -
Other Noncurrent Operating Liabilities
98 80 31 0.00 0.58 0.00 - - - -
Total Equity & Noncontrolling Interests
57 191 110 16 114 179 0.94 17 22 46
Total Preferred & Common Equity
57 191 110 16 114 179 0.94 17 22 46
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -
Total Common Equity
57 191 110 16 114 179 0.94 17 22 46
Common Stock
1,180 1,027 706 425 393 355 108 93 69 67
Retained Earnings
-1,123 -836 -596 -409 -279 -176 -108 -77 -48 -20

Quarterly Balance Sheets for Axsome Therapeutics

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
597 561 548 546 601 612 389 339
Total Current Assets
495 479 463 460 512 520 304 252
Cash & Equivalents
301 327 316 331 417 437 247 228
Accounts Receivable
161 124 120 101 78 67 45 20
Inventories, net
16 14 15 16 9.99 9.25 7.94 2.10
Prepaid Expenses
16 13 12 12 6.80 5.91 5.20 2.46
Plant, Property, & Equipment, net
0.77 0.68 0.72 0.81 0.97 0.74 0.70 0.63
Total Noncurrent Assets
101 82 84 84 88 91 84 86
Goodwill
12 12 12 12 12 12 10 12
Intangible Assets
45 49 50 52 55 57 58 61
Other Noncurrent Operating Assets
44 21 22 21 21 23 16 13
Total Liabilities & Shareholders' Equity
597 561 548 546 601 612 389 339
Total Liabilities
543 469 445 402 331 333 277 182
Total Current Liabilities
244 196 187 144 115 115 101 60
Short-Term Debt
8.60 8.13 7.04 6.39 6.67 6.34 6.00 7.00
Accounts Payable
235 186 178 137 108 108 95 53
Other Current Liabilities
0.45 1.63 1.42 1.15 0.44 0.35 0.11 0.42
Total Noncurrent Liabilities
300 272 259 258 217 218 177 121
Long-Term Debt
181 180 179 179 177 177 148 94
Capital Lease Obligations
3.68 2.95 3.03 1.70 - - - -
Other Noncurrent Operating Liabilities
114 89 76 77 39 41 29 27
Total Equity & Noncontrolling Interests
53 93 103 144 270 279 112 157
Total Preferred & Common Equity
53 93 103 144 270 279 112 157
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
53 93 103 144 270 279 112 157
Common Stock
1,235 1,141 1,086 1,048 1,006 954 719 692
Retained Earnings
-1,182 -1,048 -983 -904 -737 -675 -608 -535

Annual Metrics And Ratios for Axsome Therapeutics

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
42.53% 440.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-21.38% -27.89% -40.76% -25.72% -47.66% -124.62% -8.55% 0.57% -196.76% -12.35%
EBIT Growth
-21.02% -28.94% -44.18% -25.79% -47.43% -123.74% -8.07% -0.97% -196.01% -62.41%
NOPAT Growth
-21.02% -28.94% -44.18% -25.79% -47.43% -104.72% -20.92% 1.38% -199.51% -62.13%
Net Income Growth
-20.05% -27.84% -43.50% -26.73% -50.56% -120.71% -6.99% -6.40% -122.77% -103.49%
EPS Growth
-13.66% -14.57% -32.56% -25.27% -37.81% -74.78% 9.45% 10.56% -39.22% -54.55%
Operating Cash Flow Growth
11.49% -24.52% -7.66% -37.94% -69.18% -54.31% -13.53% -24.39% -186.08% -61.84%
Free Cash Flow Firm Growth
1.36% 8.83% -79.24% -26.63% -116.25% -31.51% -43.03% -8.90% -221.23% 0.00%
Invested Capital Growth
-518.31% -221.03% 140.79% 0.04% -2.13% -248.18% 16.98% -38.89% -233.38% 0.00%
Revenue Q/Q Growth
13.96% 21.11% 94.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
8.86% -20.74% -17.24% -26.71% 15.47% -28.81% 0.00% 0.00% -18.57% 0.00%
EBIT Q/Q Growth
8.38% -19.83% -17.91% -26.33% 15.23% -28.66% 0.00% 0.00% -18.89% 0.00%
NOPAT Q/Q Growth
8.38% -19.83% -17.91% -26.33% 15.23% -28.66% 0.00% 0.00% -19.38% 0.00%
Net Income Q/Q Growth
7.63% -18.54% -17.05% -24.83% 14.01% -28.63% 0.00% 0.00% -17.06% 0.00%
EPS Q/Q Growth
9.24% -15.57% -13.30% -3.27% -2.59% -24.07% 0.00% 0.00% -10.94% 0.00%
Operating Cash Flow Q/Q Growth
3.14% -1.97% 1.08% -8.29% -3.96% -20.14% -13.19% 3.38% -30.44% 0.00%
Free Cash Flow Firm Q/Q Growth
-5.08% -0.66% 2.34% -33.41% 13.66% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
-53.14% -128.98% -71.15% 4.30% -14.10% -24.89% 0.00% 0.00% 6.97% 0.00%
Profitability Metrics
- - - - - - - - - -
Gross Margin
91.37% 90.37% 89.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-69.99% -82.19% -347.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-72.74% -85.67% -359.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-72.74% -85.67% -359.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-74.47% -88.41% -373.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.03% 100.40% 100.00% 100.00% 99.95% 99.80% 99.30% 99.29% 98.29% 97.80%
Interest Burden Percent
102.34% 102.78% 104.08% 104.57% 103.85% 101.84% 103.75% 104.82% 100.48% 134.18%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-231.63% -159.21% -298.97% -201.51% -70.36% -76.08% -350.78% -151.19% -79.99% -26.29%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -1,763.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-48.51% -50.41% -85.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-49.66% -52.02% -89.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-231.63% -159.21% -298.97% -201.51% -70.36% -76.08% -350.78% -151.19% -79.99% -26.29%
Return on Equity Simple (ROE_SIMPLE)
-503.76% -125.27% -170.81% -834.29% -90.43% -38.24% -3,301.50% -173.14% -126.10% -26.29%
Net Operating Profit after Tax (NOPAT)
-196 -162 -126 -87 -69 -47 -23 -19 -19 -6.44
NOPAT Margin
-50.92% -59.97% -251.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-55.87% -50.90% -88.76% -49.85% -19.97% -20.55% -51.20% -38.96% -21.15% -24.04%
Return On Investment Capital (ROIC_SIMPLE)
-78.89% -43.22% -60.01% - - - - - - -
Cost of Revenue to Revenue
8.63% 9.63% 10.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
106.65% 119.41% 318.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
48.50% 36.20% 115.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
164.11% 176.04% 448.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-281 -232 -180 -125 -99 -67 -30 -28 -28 -9.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-270 -222 -174 -124 -98 -67 -30 -27 -27 -9.25
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
71.92 19.72 30.57 91.10 26.74 19.96 89.64 7.93 5.99 0.00
Price to Tangible Book Value (P/TBV)
0.00 29.97 84.61 91.10 26.74 19.96 89.64 7.93 5.99 0.00
Price to Revenue (P/Rev)
10.63 13.92 66.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 366.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
10.31 13.17 64.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
3.37 0.97 0.91 3.14 0.42 0.11 7.37 0.59 0.45 0.00
Long-Term Debt to Equity
3.22 0.93 0.86 3.14 0.42 0.10 3.86 0.40 0.44 0.00
Financial Leverage
-1.31 -1.01 -1.10 -1.34 -1.15 -1.15 -1.76 -1.33 -1.10 -1.03
Leverage Ratio
4.66 3.06 3.35 2.12 1.39 1.31 2.89 1.93 1.28 1.06
Compound Leverage Factor
4.77 3.15 3.49 2.21 1.44 1.34 2.99 2.02 1.29 1.42
Debt to Total Capital
77.10% 49.13% 47.76% 75.85% 29.81% 10.03% 88.05% 37.27% 31.11% 0.00%
Short-Term Debt to Total Capital
3.33% 1.71% 2.81% 0.00% 0.00% 1.31% 41.94% 12.27% 0.86% 0.00%
Long-Term Debt to Total Capital
73.77% 47.43% 44.95% 75.85% 29.81% 8.72% 46.11% 25.00% 30.25% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
22.90% 50.87% 52.24% 24.15% 70.19% 89.97% 11.95% 62.73% 68.89% 100.00%
Debt to EBITDA
-0.71 -0.83 -0.58 -0.40 -0.49 -0.30 -0.23 -0.36 -0.35 0.00
Net Debt to EBITDA
0.46 0.91 0.58 0.30 1.38 3.01 0.24 0.88 0.98 0.00
Long-Term Debt to EBITDA
-0.68 -0.80 -0.54 -0.40 -0.49 -0.26 -0.12 -0.24 -0.35 0.00
Debt to NOPAT
-0.98 -1.14 -0.80 -0.56 -0.70 -0.42 -0.30 -0.52 -0.51 0.00
Net Debt to NOPAT
0.63 1.24 0.80 0.43 1.95 4.25 0.31 1.27 1.39 0.00
Long-Term Debt to NOPAT
-0.94 -1.10 -0.75 -0.56 -0.70 -0.37 -0.16 -0.35 -0.49 0.00
Altman Z-Score
1.63 3.60 5.44 1.49 22.41 50.11 -12.40 -0.59 1.51 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.11 3.63 2.54 3.75 7.85 9.00 1.41 2.90 5.30 18.63
Quick Ratio
1.99 3.46 2.47 3.75 7.85 8.98 1.29 2.79 5.11 18.25
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-141 -143 -156 -87 -69 -32 -24 -17 -16 -4.85
Operating Cash Flow to CapEx
-47,559.26% -24,927.84% -16,597.01% -35,138.31% -170,962.87% -287,668.62% -91,918.59% -267,444.45% -20,353.00% -36,835.81%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -55.29 0.00 0.00 0.00 0.00 -1.98
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 -62.92 0.00 0.00 0.00 0.00 -3.04
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -62.95 0.00 0.00 0.00 0.00 -3.05
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.67 0.59 0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
3.26 4.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
2.16 2.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
539.43 345.15 99.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.19 0.24 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
112.06 89.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
169.15 136.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,924.37 1,550.29 3,956.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
-1,643.17 -1,324.70 -3,956.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-66 -11 8.87 -22 -22 -21 -6.12 -7.37 -5.31 -1.59
Invested Capital Turnover
-10.00 -290.03 -7.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-56 -20 31 0.01 -0.45 -15 1.25 -2.06 -3.72 -1.59
Enterprise Value (EV)
3,977 3,564 3,249 1,387 2,907 3,367 77 108 102 0.00
Market Capitalization
4,100 3,766 3,349 1,424 3,042 3,567 84 133 129 0.00
Book Value per Share
$1.18 $4.04 $2.52 $0.41 $3.06 $5.18 $0.03 $0.71 $1.13 $3.89
Tangible Book Value per Share
($0.04) $2.66 $0.91 $0.41 $3.06 $5.18 $0.03 $0.71 $1.13 $3.89
Total Capital
249 375 210 65 162 199 7.85 27 31 46
Total Debt
192 184 100 49 48 20 6.91 9.93 9.74 0.00
Total Long-Term Debt
184 178 94 49 48 17 3.62 6.66 9.47 0.00
Net Debt
-123 -202 -101 -37 -136 -200 -7.06 -24 -27 -48
Capital Expenditures (CapEx)
0.27 0.58 0.70 0.31 0.05 0.02 0.03 0.01 0.10 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-52 -14 -46 -23 -23 -21 -6.28 -7.63 -5.52 -1.64
Debt-free Net Working Capital (DFNWC)
263 372 155 63 161 198 7.68 26 31 46
Net Working Capital (NWC)
255 365 149 63 161 196 4.39 23 31 46
Net Nonoperating Expense (NNE)
91 77 61 43 34 21 7.97 9.93 7.92 5.77
Net Nonoperating Obligations (NNO)
-123 -202 -101 -37 -136 -200 -7.06 -24 -27 -48
Total Depreciation and Amortization (D&A)
11 9.41 5.89 1.15 0.86 0.69 0.42 0.51 0.09 0.05
Debt-free, Cash-free Net Working Capital to Revenue
-13.51% -5.31% -91.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
68.25% 137.40% 309.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
66.10% 135.04% 297.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding
47.91M 45.43M 40.66M 38.48M 37.41M 37.08M 33.28M 25.49M 19.20M 11.95M
Adjusted Diluted Earnings per Share
($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Adjusted Weighted Average Diluted Shares Outstanding
47.91M 45.43M 40.66M 38.48M 37.41M 37.08M 33.28M 25.49M 19.20M 11.95M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Adjusted Weighted Average Basic & Diluted Shares Outstanding
48.77M 47.37M 43.52M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M
Normalized Net Operating Profit after Tax (NOPAT)
-196 -162 -126 -87 -69 -47 -23 -19 -19 -6.44
Normalized NOPAT Margin
-50.92% -59.97% -251.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-74.45% -88.06% -373.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 -79.50 0.00 0.00 0.00 0.00 -3.81
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 -55.65 0.00 0.00 0.00 0.00 -2.63
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -79.54 0.00 0.00 0.00 0.00 -3.81
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 -55.69 0.00 0.00 0.00 0.00 -2.64
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.28% -6.55% -3.73% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Axsome Therapeutics

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
61.95% 66.04% 81.27% 86.65% -20.70% 193.50% 243.07% 429.48% 0.00% 0.00% 0.00%
EBITDA Growth
16.42% 27.31% -0.24% -20.74% -1,470.37% -66.00% -48.34% -64.35% 89.07% -79.17% -19.63%
EBIT Growth
15.30% 26.11% -0.81% -19.97% -955.46% -64.02% -46.47% -66.04% 83.35% -83.75% -26.95%
NOPAT Growth
15.30% 26.11% -0.81% -19.97% -955.46% -64.02% -46.47% -66.04% 83.35% -83.75% -26.95%
Net Income Growth
13.08% 24.06% -3.86% -18.13% -509.35% -61.09% -38.77% -62.10% 71.69% -80.25% -28.50%
EPS Growth
15.28% 28.37% -1.52% -8.44% -453.85% -49.31% -23.36% -45.28% 74.76% -60.00% -15.05%
Operating Cash Flow Growth
18.88% 13.70% 65.21% 45.60% -818.52% -10.15% -135.29% -65.04% 82.17% 4.43% 15.01%
Free Cash Flow Firm Growth
149.10% 109.82% 173.47% 78.17% 37.49% 32.23% 40.14% 67.41% -70.33% -217.80% -321.64%
Invested Capital Growth
-8,465.13% -518.31% -216.99% -194.19% -103.34% -221.03% 20.51% -39.70% 191.38% 140.79% 235.29%
Revenue Q/Q Growth
2.27% 13.37% 20.19% 16.22% 4.85% 23.77% 23.76% -50.62% 288.07% 44.67% 91.00%
EBITDA Q/Q Growth
22.42% -16.61% 20.58% -16.33% 32.53% -60.80% 4.34% -1,413.06% 92.87% -43.70% -5.99%
EBIT Q/Q Growth
21.53% -15.96% 19.76% -16.01% 31.54% -58.20% 4.51% -920.66% 89.36% -41.27% -8.25%
NOPAT Q/Q Growth
21.53% -15.96% 19.76% -16.01% 31.54% -58.20% 4.51% -920.66% 89.36% -41.27% -8.25%
Net Income Q/Q Growth
20.69% -15.96% 18.58% -16.07% 30.71% -58.61% 7.40% -498.77% 81.68% -36.63% -8.17%
EPS Q/Q Growth
20.78% -14.93% 19.76% -15.97% 33.02% -62.88% 14.29% -492.31% 81.94% -34.58% -0.94%
Operating Cash Flow Q/Q Growth
-65.54% -40.64% 38.12% 43.68% -76.10% 43.30% 3.25% -850.85% 78.88% -21.11% 32.14%
Free Cash Flow Firm Q/Q Growth
180.13% -86.80% 674.39% 76.88% 43.98% 1.23% -70.64% 33.79% 39.27% 12.75% 7.11%
Invested Capital Q/Q Growth
18.61% -53.14% -85.22% -3,609.98% 94.12% -128.98% 49.12% 31.41% 113.14% -71.15% -25.38%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
91.94% 91.15% 91.95% 90.76% 91.60% 89.69% 88.70% 90.15% 92.01% 90.60% 88.58%
EBITDA Margin
-44.61% -58.80% -57.17% -86.52% -86.43% -134.32% -103.38% -133.75% -4.36% -237.49% -239.10%
Operating Margin
-46.91% -61.14% -59.78% -89.54% -89.70% -137.39% -107.49% -139.31% -6.74% -245.85% -251.76%
EBIT Margin
-46.91% -61.14% -59.78% -89.54% -89.70% -137.39% -107.49% -139.31% -6.74% -245.85% -251.76%
Profit (Net Income) Margin
-48.91% -63.08% -61.67% -91.03% -91.14% -137.92% -107.62% -143.83% -11.86% -251.29% -266.08%
Tax Burden Percent
100.00% 100.11% 100.00% 100.00% 100.00% 99.67% 98.92% 99.09% 129.87% 100.00% 100.00%
Interest Burden Percent
104.27% 103.04% 103.16% 101.66% 101.61% 100.71% 101.22% 104.20% 135.52% 102.21% 105.68%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -25,321.38% -1,724.41% 0.00% -495.80% -538.73% 0.00% 0.00% -1,127.57%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -25,308.38% -1,706.51% 0.00% -485.37% -519.75% 0.00% 0.00% -1,111.81%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 25,212.69% 1,584.57% 0.00% 408.26% 402.95% 0.00% 0.00% 1,067.23%
Return on Equity (ROE)
-282.16% -231.63% -171.61% -108.69% -139.84% -159.21% -87.54% -135.77% -250.92% -298.97% -60.34%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -418.00% -318.68% -756.81% -1,763.61% -521.00%
Operating Return on Assets (OROA)
-35.49% -40.77% -34.81% -45.00% -48.17% -80.85% -51.11% -64.18% -4.08% -58.68% -28.37%
Return on Assets (ROA)
-37.01% -42.06% -35.91% -45.75% -48.94% -81.16% -51.17% -66.27% -7.18% -59.98% -29.98%
Return on Common Equity (ROCE)
-282.16% -231.63% -171.61% -108.69% -139.84% -159.21% -87.54% -135.77% -250.92% -298.97% -60.34%
Return on Equity Simple (ROE_SIMPLE)
-523.02% 0.00% -334.73% -300.00% -205.77% 0.00% -74.89% -66.16% -141.95% 0.00% -101.59%
Net Operating Profit after Tax (NOPAT)
-40 -51 -44 -55 -47 -69 -43 -46 -4.46 -42 -30
NOPAT Margin
-32.84% -42.80% -41.84% -62.68% -62.79% -96.17% -75.24% -97.52% -4.72% -172.10% -176.23%
Net Nonoperating Expense Percent (NNEP)
-15.50% -14.81% -11.26% -13.00% -17.90% -19.75% -10.42% -18.98% -10.53% -27.96% -15.76%
Return On Investment Capital (ROIC_SIMPLE)
-16.16% -20.42% - - - -18.32% - - - -20.00% -
Cost of Revenue to Revenue
8.06% 8.85% 8.05% 9.24% 8.40% 10.31% 11.30% 9.85% 7.99% 9.40% 11.42%
SG&A Expenses to Revenue
99.44% 95.37% 91.22% 118.80% 131.96% 121.36% 143.94% 169.03% 78.45% 252.34% 242.74%
R&D to Revenue
36.87% 46.31% 43.32% 57.19% 49.11% 43.06% 49.78% 44.07% 18.81% 60.29% 88.31%
Operating Expenses to Revenue
138.85% 152.29% 151.72% 180.30% 181.31% 227.07% 196.18% 229.46% 98.75% 336.45% 340.34%
Earnings before Interest and Taxes (EBIT)
-57 -73 -63 -78 -67 -98 -62 -65 -6.37 -60 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-54 -70 -60 -75 -65 -96 -60 -62 -4.13 -58 -40
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
106.90 71.92 46.44 37.17 26.22 19.72 12.24 11.23 24.01 30.57 11.43
Price to Tangible Book Value (P/TBV)
0.00 0.00 133.33 93.93 47.03 29.97 16.28 14.89 61.83 84.61 21.36
Price to Revenue (P/Rev)
13.16 10.63 12.75 13.12 15.04 13.92 14.76 17.16 18.56 66.94 70.07
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 82.72 115.77 137.01 366.14 54.36
Enterprise Value to Revenue (EV/Rev)
12.91 10.31 12.34 12.68 14.47 13.17 13.72 15.77 17.92 64.93 65.14
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
3.64 3.37 2.06 1.84 1.30 0.97 0.68 0.66 1.37 0.91 0.64
Long-Term Debt to Equity
3.48 3.22 1.97 1.77 1.25 0.93 0.66 0.63 1.32 0.86 0.60
Financial Leverage
-1.28 -1.31 -1.02 -1.00 -0.93 -1.01 -0.84 -0.78 -1.01 -1.10 -0.96
Leverage Ratio
5.79 4.66 3.21 3.04 3.65 3.06 2.20 2.69 3.78 3.35 2.28
Compound Leverage Factor
6.04 4.81 3.31 3.09 3.71 3.08 2.23 2.81 5.12 3.42 2.41
Debt to Total Capital
78.45% 77.10% 67.29% 64.81% 56.46% 49.13% 40.59% 39.65% 57.87% 47.76% 39.07%
Short-Term Debt to Total Capital
3.48% 3.33% 2.86% 2.41% 1.93% 1.71% 1.47% 1.37% 2.26% 2.81% 2.71%
Long-Term Debt to Total Capital
74.96% 73.77% 64.42% 62.40% 54.53% 47.43% 39.12% 38.28% 55.61% 44.95% 36.36%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
21.55% 22.90% 32.71% 35.19% 43.54% 50.87% 59.41% 60.35% 42.13% 52.24% 60.93%
Debt to EBITDA
-0.75 -0.71 -0.65 -0.64 -0.66 -0.83 -1.00 -1.11 -1.10 -0.58 -0.68
Net Debt to EBITDA
0.41 0.46 0.46 0.43 0.51 0.91 1.26 1.54 0.66 0.58 0.85
Long-Term Debt to EBITDA
-0.71 -0.68 -0.62 -0.62 -0.64 -0.80 -0.96 -1.07 -1.05 -0.54 -0.63
Debt to NOPAT
-1.02 -0.98 -0.89 -0.89 -0.91 -1.14 -1.36 -1.51 -1.48 -0.80 -0.95
Net Debt to NOPAT
0.57 0.63 0.64 0.59 0.71 1.24 1.72 2.09 0.90 0.80 1.19
Long-Term Debt to NOPAT
-0.98 -0.94 -0.85 -0.85 -0.88 -1.10 -1.31 -1.45 -1.43 -0.75 -0.88
Altman Z-Score
4.42 2.84 3.75 3.31 4.07 4.35 5.08 4.84 4.57 6.63 4.07
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.03 2.11 2.44 2.48 3.20 3.63 4.46 4.52 3.02 2.54 4.19
Quick Ratio
1.90 1.99 2.30 2.34 3.01 3.46 4.32 4.39 2.89 2.47 4.11
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
14 4.83 37 -6.37 -28 -49 -50 -29 -44 -73 -83
Operating Cash Flow to CapEx
-12,832.84% -87,340.00% -20,701.11% -57,903.85% -54,558.16% -433,742.86% -14,433.42% -41,615.79% -8,198.59% -15,228.18% -34,481.82%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.76 0.67 0.58 0.50 0.54 0.59 0.48 0.46 0.61 0.24 0.11
Accounts Receivable Turnover
3.29 3.26 3.34 3.11 3.43 4.08 4.53 4.37 0.00 0.00 0.00
Inventory Turnover
2.31 2.16 2.49 2.31 2.11 2.68 3.47 1.67 0.00 0.00 0.00
Fixed Asset Turnover
545.31 539.43 409.26 399.30 331.38 345.15 279.65 266.29 248.49 99.49 54.50
Accounts Payable Turnover
0.20 0.19 0.21 0.20 0.21 0.24 0.26 0.23 0.22 0.09 0.08
Days Sales Outstanding (DSO)
110.99 112.06 109.20 117.55 106.31 89.37 80.63 83.58 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
158.23 169.15 146.70 158.03 173.06 136.22 105.16 218.24 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,841.94 1,924.37 1,778.48 1,849.36 1,699.86 1,550.29 1,395.57 1,607.53 1,690.30 3,956.17 4,814.76
Cash Conversion Cycle (CCC)
-1,572.71 -1,643.17 -1,522.58 -1,573.79 -1,420.49 -1,324.70 -1,209.78 -1,305.71 -1,690.30 -3,956.17 -4,814.76
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-54 -66 -43 -23 -0.63 -11 37 25 19 8.87 31
Invested Capital Turnover
-15.81 -10.00 -107.50 404.00 27.46 -290.03 6.59 5.52 -162.02 -7.77 6.40
Increase / (Decrease) in Invested Capital
-53 -56 -80 -48 -20 -20 6.31 -16 40 31 53
Enterprise Value (EV)
5,580 3,977 4,178 3,697 3,631 3,564 3,066 2,877 2,591 3,249 1,672
Market Capitalization
5,688 4,100 4,314 3,823 3,776 3,766 3,298 3,131 2,684 3,349 1,798
Book Value per Share
$1.09 $1.18 $1.94 $2.17 $3.04 $4.04 $5.71 $6.40 $2.57 $2.52 $3.90
Tangible Book Value per Share
($0.09) ($0.04) $0.67 $0.86 $1.69 $2.66 $4.29 $4.83 $1.00 $0.91 $2.09
Total Capital
247 249 284 292 331 375 454 462 265 210 258
Total Debt
194 192 191 189 187 184 184 183 154 100 101
Total Long-Term Debt
185 184 183 182 180 178 177 177 148 94 94
Net Debt
-107 -123 -136 -126 -145 -202 -232 -254 -93 -101 -127
Capital Expenditures (CapEx)
0.34 0.03 0.09 0.05 0.10 0.01 0.37 0.13 0.07 0.18 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-42 -52 -36 -32 -8.61 -14 -13 -26 -37 -46 -28
Debt-free Net Working Capital (DFNWC)
259 263 291 283 323 372 404 411 210 155 199
Net Working Capital (NWC)
251 255 283 276 316 365 397 405 204 149 192
Net Nonoperating Expense (NNE)
20 24 21 25 21 30 19 22 6.76 19 15
Net Nonoperating Obligations (NNO)
-107 -123 -136 -126 -145 -202 -232 -254 -93 -101 -127
Total Depreciation and Amortization (D&A)
2.80 2.78 2.73 2.63 2.45 2.19 2.37 2.60 2.25 2.04 2.13
Debt-free, Cash-free Net Working Capital to Revenue
-9.62% -13.51% -10.72% -11.03% -3.43% -5.31% -5.72% -14.28% -25.39% -91.65% -110.73%
Debt-free Net Working Capital to Revenue
60.01% 68.25% 86.00% 97.26% 128.61% 137.40% 180.71% 225.24% 145.07% 309.73% 775.74%
Net Working Capital to Revenue
58.02% 66.10% 83.59% 94.84% 126.06% 135.04% 177.72% 221.77% 140.93% 297.94% 748.46%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Adjusted Weighted Average Basic Shares Outstanding
48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Adjusted Diluted Earnings per Share
($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Adjusted Weighted Average Diluted Shares Outstanding
48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
49.24M 48.77M 48.46M 48.00M 47.50M 47.37M 47.32M 47.19M 43.57M 43.52M 43.43M
Normalized Net Operating Profit after Tax (NOPAT)
-40 -51 -44 -55 -47 -69 -43 -46 -4.46 -42 -30
Normalized NOPAT Margin
-32.84% -42.80% -41.84% -62.68% -62.79% -96.17% -75.24% -97.52% -4.72% -172.10% -176.23%
Pre Tax Income Margin
-48.91% -63.00% -61.67% -91.03% -91.14% -138.37% -108.80% -145.15% -9.13% -251.29% -266.08%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.43% -0.28% -0.16% -0.74% 0.00% -6.55% -7.76% -10.21% 0.00% -3.73% 0.00%

Frequently Asked Questions About Axsome Therapeutics' Financials

When does Axsome Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Axsome Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Axsome Therapeutics' net income changed over the last 9 years?

Axsome Therapeutics' net income appears to be on an upward trend, with a most recent value of -$287.22 million in 2024, rising from -$12.21 million in 2015. The previous period was -$239.24 million in 2023. View Axsome Therapeutics' forecast to see where analysts expect Axsome Therapeutics to go next.

What is Axsome Therapeutics's operating income?
Axsome Therapeutics's total operating income in 2024 was -$280.56 million, based on the following breakdown:
  • Total Gross Profit: $352.39 million
  • Total Operating Expenses: $632.95 million
How has Axsome Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' total revenue changed from $0.00 in 2015 to $385.69 million in 2024, a change of 38,569,300,000.0%.

How much debt does Axsome Therapeutics have?

Axsome Therapeutics' total liabilities were at $511.48 million at the end of 2024, a 28.8% increase from 2023, and a 19,334.0% increase since 2015.

How much cash does Axsome Therapeutics have?

In the past 9 years, Axsome Therapeutics' cash and equivalents has ranged from $13.97 million in 2018 to $386.19 million in 2023, and is currently $315.35 million as of their latest financial filing in 2024.

How has Axsome Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' book value per share changed from 3.89 in 2015 to 1.18 in 2024, a change of -69.7%.



This page (NASDAQ:AXSM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners